2013至2017年晚期黑色素瘤患者生存结局:全国人群登记研究
该研究基于荷兰全国人群登记数据,分析2013至2017年诊断的晚期黑色素瘤患者(n=3616)的生存结局及预后因素随时间的变化。2013和2016队列的中位总生存期分别为11.7个月和17.7个月,2016队列在0-6个月和6-48个月的风险比均优于2013队列。多数预后因素在诊断后前6个月影响更强,BRAF突变仅在前6个月与更优生存相关。
要点
- 2016队列中位OS为17.7个月,优于2013队列的11.7个月。
- 2016队列0-6个月HR=0.55,6-48个月HR=0.68,均优于2013队列。
- BRAF突变仅在前6个月与更优生存相关(HR=0.50)。
核心结论
- 荷兰晚期黑色素瘤预后从2013至2016年有所改善。
- 多数评估的预后因素在诊断后前6个月影响更强。
- BRAF突变仅在前6个月与更优生存相关。
研究设计与样本
- 基于荷兰全国人群登记数据的回顾性队列分析。
- 纳入2013至2017年诊断的晚期黑色素瘤患者3616例。
- 采用限制于前6个月的多变量Cox模型和6至48个月的多变量landmark Cox模型评估总生存期,2017队列因随访时间短被排除。
主要发现
- 2013队列中位OS为11.7个月(95%CI: 10.4-13.5),2016队列为17.7个月(95%CI: 14.9-19.8)。
- 与2013队列相比,2016队列0-6个月HR=0.55(95%CI: 0.43-0.72),6-48个月HR=0.68(95%CI: 0.57-0.83)。
- LDH升高、≥3个器官远处转移、脑和肝转移、ECOG PS≥1在0-6个月与不良生存的关联强于6-48个月。
- BRAF突变黑色素瘤在前6个月与更优生存相关(HR=0.50,95%CI: 0.42-0.59)。
临床怎么用
- 晚期黑色素瘤预后随时间改善,临床决策可参考诊断年份对应的生存预期。
- 诊断后前6个月应重点关注LDH升高、多器官转移、脑肝转移及ECOG PS≥1等高危因素。
- BRAF突变状态对短期(前6个月)生存的预测价值更明显。
局限性
- 2017队列因随访时间短被排除在生存分析之外。
- 分析仅纳入无缺失值的病例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The treatment landscape has completely changed for advanced melanoma. We report survival outcomes and the differential impact of prognostic factors over time in daily clinical practice. METHODS: From a Dutch nationwide population-based registry, patients with advanced melanoma diagnosed from 2013 to 2017 were analysed (n = 3616). Because the proportional hazards assumption was violated, a multivariable Cox model restricted to the first 6 months and a multivariable landmark Cox model from 6 to 48 months were used to assess overall survival (OS) of cases without missing values. The 2017 cohort was excluded from this analysis because of the short follow-up time. RESULTS: Median OS of the 2013 and 2016 cohort was 11.7 months (95% confidence interval [CI]: 10.4-13.5) and 17.7 months (95% CI: 14.9-19.8), respectively. Compared with the 2013 cohort, the 2016 cohort had superior survival in the Cox model from 0 to 6 months (hazard ratio [HR] = 0.55 [95% CI: 0.43-0.72]) and in the Cox model from 6 to 48 months (HR = 0.68 [95% CI: 0.57-0.83]). Elevated lactate dehydrogenase levels, distant metastases in ≥3 organ sites, brain and liver metastasis and Eastern Cooperative Oncology Group performance score of ≥1 had stronger association with inferior survival from 0 to 6 months than from 6 to 48 months. BRAF-mutated melanoma had superior survival in the first 6 months (HR = 0.50 [95% CI: 0.42-0.59]). CONCLUSION(S): Prognosis for advanced melanoma in the Netherlands has improved from 2013 to 2016. Prognostic importance of most evaluated factors was higher in the first 6 months after diagnosis. BRAF-mutated melanoma was only associated with superior survival in the first 6 months.
引用
- van Zeijl MCT, de Wreede LC, van den Eertwegh AJM, et al. Survival outcomes of patients with advanced melanoma from 2013 to 2017: Results of a nationwide population-based registry. Eur J Cancer. 2020. PMID: 33373869. doi:10.1016/j.ejca.2020.11.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。